| Enzyme-Linked Immunosorbent Assay for Campylobacter pyloridis: Correlation with Presence of C. pyloridis in the Gastric Mucosa CS Goodwin, E Blincow, G Peterson, C Sanderson, W Cheng, B Marshall, ... Journal of Infectious Diseases 155 (3), 488-494, 1987 | 258 | 1987 |
| The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection EJ Gane, YS Lim, SC Gordon, K Visvanathan, E Sicard, RN Fedorak, ... Journal of hepatology 63 (2), 320-328, 2015 | 239 | 2015 |
| Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection K Agarwal, SK Fung, TT Nguyen, W Cheng, E Sicard, SD Ryder, ... Journal of hepatology 62 (3), 533-540, 2015 | 229 | 2015 |
| Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease M Eslam, AM Hashem, R Leung, M Romero-Gomez, T Berg, GJ Dore, ... Nature communications 6 (1), 6422, 2015 | 177 | 2015 |
| Global multi-stakeholder endorsement of the MAFLD definition N Méndez-Sánchez, E Bugianesi, RG Gish, F Lammert, H Tilg, ... The lancet Gastroenterology & hepatology 7 (5), 388-390, 2022 | 170 | 2022 |
| Hepatitis C virus drug resistance and immune‐driven adaptations: relevance to new antiviral therapy S Gaudieri, A Rauch, K Pfafferott, E Barnes, W Cheng, G McCaughan, ... Hepatology 49 (4), 1069-1082, 2009 | 169 | 2009 |
| Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection S Gaudieri, A Rauch, LP Park, E Freitas, S Herrmann, G Jeffrey, W Cheng, ... Journal of virology 80 (22), 11094-11104, 2006 | 140 | 2006 |
| Body composition in nonalcoholic cirrhosis: the effect of disease etiology and severity on nutritional compartments DHG Crawford, RW Shepherd, JW Halliday, GWGE Cooksley, SD Golding, ... Gastroenterology 106 (6), 1611-1617, 1994 | 128 | 1994 |
| MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C K Thabet, A Asimakopoulos, M Shojaei, M Romero-Gomez, A Mangia, ... Nature communications 7 (1), 12757, 2016 | 123 | 2016 |
| Dose‐dependent pharmacokinetics of caffeine in humans: relevance as a test of quantitative liver function WSC Cheng, TL Murphy, MT Smith, WGE Cooksley, JW Halliday, ... Clinical Pharmacology & Therapeutics 47 (4), 516-524, 1990 | 121 | 1990 |
| Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes M Eslam, A Mangia, T Berg, HLY Chan, WL Irving, GJ Dore, ML Abate, ... Hepatology 64 (1), 34-46, 2016 | 116 | 2016 |
| Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection MT Kitson, GJ Dore, J George, P Button, GW McCaughan, DHG Crawford, ... Journal of hepatology 58 (3), 467-472, 2013 | 106 | 2013 |
| Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial MF Yuen, K Agarwal, EJ Gane, C Schwabe, SH Ahn, DJ Kim, YS Lim, ... The lancet Gastroenterology & hepatology 5 (2), 152-166, 2020 | 104 | 2020 |
| IFN-λ3, not IFN-λ4, likely mediates IFNL3–IFNL4 haplotype–dependent hepatic inflammation and fibrosis M Eslam, D McLeod, KS Kelaeng, A Mangia, T Berg, K Thabet, WL Irving, ... Nature Genetics 49 (5), 795-800, 2017 | 101 | 2017 |
| Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir H Dvory-Sobol, D Wyles, W Ouyang, K Chodavarapu, J McNally, ... J Hepatol 62 (Suppl 2), S221, 2015 | 95 | 2015 |
| FibroGENE: A gene-based model for staging liver fibrosis M Eslam, AM Hashem, M Romero-Gomez, T Berg, GJ Dore, A Mangia, ... Journal of hepatology 64 (2), 390-398, 2016 | 87 | 2016 |
| Improvement in chronic hepatocerebral degeneration following liver transplantation EE Powell, MP Pender, JB Chalk, PJ Parkin, R Strong, S Lynch, P Kerlin, ... Gastroenterology 98 (4), 1079-1082, 1990 | 83 | 1990 |
| Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen–restricted immune pressure A Rauch, I James, K Pfafferott, D Nolan, P Klenerman, W Cheng, ... Hepatology 50 (4), 1017-1029, 2009 | 81 | 2009 |
| Long-term persistence of HCV NS5A resistance-associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir D Wyles, A Mangia, W Cheng, S Shafran, C Schwabe, W Ouyang, ... Antiviral therapy 23 (3), 229-238, 2018 | 75 | 2018 |
| Impact of high‐dose peginterferon alfa‐2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial SK Roberts, MD Weltman, DHG Crawford, GW McCaughan, W Sievert, ... Hepatology 50 (4), 1045-1055, 2009 | 71 | 2009 |
